Oncotelic and Sapu Nano Launch Revolutionary Deciparticle™ Nanomedicine
In a game-changing development, Oncotelic Therapeutics, Inc. (OTCQB: OTLC) has partnered with Sapu Nano to unveil their innovative Deciparticle™ platform. This groundbreaking technology is designed to effectively formulate a variety of hydrophobic drugs, including macrolide mTOR inhibitors and polyketides, enabling enhanced delivery methods for those with intravenous (IV) needs.
Key Findings Highlight Enhanced Drug Formulation Capabilities
Recent data presented by Sapu Nano reveals that the Deciparticle™ technology excels at crafting nanoparticles with a size of under 20 nm, broadening the scope of therapies it can support. This robust capability allows the encapsulation of numerous hydrophobic therapeutics while ensuring consistency and stability, a major leap forward in the nanomedicine field.
Understanding the Deciparticle™ Platform's Versatility
The Deciparticle™ platform has been proven to create effective formulations of macrolide drugs, which are crucial in immunosuppression. Five clinically significant macrolide immunosuppressants, namely Sirolimus, Temsirolimus, Ridaforolimus, Umirolimus, and Everolimus, are now stable within Deciparticle™ formulations. This versatility stems from the platform's ability to maintain nanoparticle integrity despite structural diversities in these compounds.
Exploring Additional Therapeutic Class Capabilities
Moreover, the Deciparticle™ technology effectively encapsulates ascomycin macrolactams such as Tacrolimus and Pimecrolimus, demonstrating a flexible approach to drug design. Interestingly, while Tacrolimus formed stable nanoparticles, Pimecrolimus exceeded the size limit, showcasing the platform's design boundaries.
Expanding Horizons: Peptides and Other Drugs
One of the standout features of the Deciparticle™ platform is its capacity to work with various peptide types. Critical peptide classes like Cyclosporine A and Exenatide have been successfully encapsulated, illustrating the platform's adaptability. Such formulations are vital in ensuring effective delivery for peptide-based therapies, which often face solubility challenges.
Manufacturing and Scalability: A Focus on Quality
The success of the Deciparticle™ platform is supported by Sapu Nano's state-of-the-art ISO-5 cGMP manufacturing facility, which ensures high-quality production standards. Processes such as one-pot bulk manufacturing, sterile filtration, and automated fill/finish contribute to the platform’s efficiency. Notably, this enables rapid progression from formulation to clinical trial supplies, supporting multiple Investigational New Drug (IND) applications each year.
Advancing Drug Delivery Technologies
As stated by Dr. Vuong Trieu, CEO of Sapu Nano, the Deciparticle™ platform represents a significant shift away from traditional delivery methods, proving effective for a wide range of hydrophobic substances previously hindered by delivery issues. This advancement demonstrates a commitment to enhancing drug delivery across various therapeutic areas, including oncology and immunology.
Conclusion: A Bright Future for Nanomedicine
The Deciparticle™ platform is not just a technological advancement; it embodies a broader vision for the future of drug delivery in medicine. With ongoing research and increasing capabilities, Oncotelic is well-positioned to make meaningful improvements in the treatment of patients, particularly in areas where existing therapies have fallen short.
About Sapu Nano
Sapu Nano continues to lead in developing Deciparticle™ nanomedicine, seeking to optimize hydrophobic drug delivery. Their commitment to innovation is evident in their robust cGMP manufacturing capabilities, facilitating the rapid transition from research to clinical application.
Frequently Asked Questions
What is the Deciparticle™ platform?
The Deciparticle™ platform is an advanced nanotechnology enabling the formulation of a wide array of hydrophobic drugs into stable nanoparticles for better drug delivery.
What types of drugs can be formulated using this technology?
This platform supports various classes of drugs, including macrolide mTOR inhibitors, cyclic and linear peptides, and ascomycin macrolactams.
How does the manufacturing process work?
Sapu Nano employs an ISO-5 cGMP facility that supports efficient processes such as one-pot manufacturing and automated filling, aimed at quality and scalability.
Who benefits from the Deciparticle™ technology?
This technology primarily benefits patients requiring improved drug delivery options, particularly in oncology and immunology therapies.
Who is Oncotelic Therapeutics, Inc.?
Oncotelic Therapeutics, Inc. is a biotechnology company focused on enhancing treatment outcomes in cancer patients, emphasizing pediatric cancers and innovative drug delivery systems.
